1. Directional coupling technology The ADC drugs currently in the forefront of the development all use traditional conjugation technology (no-specific conjugation). The biggest disadvantage is
1. Antibody molecules At present, the antibody molecules of ADC drugs often use humanized monoclonal antibodies, and the crystallizable fragment (Fc) segment is modified to
1. Circulation, ADC drugs are administered by systemic exposure, and first enter the blood system. Since the relative molecular mass of antibodies is about 150ku,
Antibody-drug conjugate (ADC) is to link a biologically active small-molecule drug to a monoclonal antibody through a chemical link, and the monoclonal antibody acts as
